Afya Targets 200 New Med School Seats, Forecasts Double-Digit SPM Growth
Afya faces uncertainty over new regulations and potential penalties for underperforming schools as it prepares for the September Ahmed exam with near-full occupancy. Soft B2B revenues in its medical practice solutions segment contrasted with Q4 investments boosting SPM and continued education, underpinning double-digit growth guidance.
1. Regulatory Outlook and Ahmed Exam Prep
Afya reports intake for its schools is nearly complete with high occupancy as it readies for the new Ahmed exam in September. Management is assessing emerging regulations that could impose penalties on underperforming schools and has action plans to ensure compliance and maintain student standards.
2. B2B Revenues and Strategic Investments
B2B sales in the medical practice solutions segment were soft over the last year, reflecting market readiness and integration challenges. Q4 investments focused on unifying products and technology under the Afya umbrella to enhance physician engagement and create new monetization channels.
3. Segment Growth Guidance for 2026
Undergraduate enrollment is expected to grow in single digits with modest ticket and volume gains. The SPM and continued education segments are projected to expand in double digits, though margins will tighten due to accelerated investment programs initiated in Q4 2025.
4. Capital Allocation and Shareholder Returns
Strong free cash flow supports Afya’s plan to add 200 medical school seats annually targeting at least 20% IRR. The company balances inorganic growth with buyback and dividend flexibility, adjusting distributions based on share price levels and net debt metrics.